A Multicenter, Randomized, Double-blind, Placebo -Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chinese Adult Males
Latest Information Update: 24 Dec 2025
At a glance
- Drugs GT 20029 (Primary)
- Indications Alopecia
- Focus Therapeutic Use
- Sponsors Suzhou Kintor Pharmaceuticals
Most Recent Events
- 01 Dec 2025 Primary endpoint has been met (Change in non-vellus hair count (TAHC, Target Area Hair Counts) within target area (change from baseline at 12 weeks of treatment)) , according to Results published in the Journal of Dermatological Treatment
- 01 Dec 2025 Results published in the Journal of Dermatological Treatment
- 18 Nov 2024 Status changed to completed.